Cayman sPLA2 (human, recombinant Type IID)

Secretory phospholipase A₂ (sPLA₂) (Type IID) is a calcium-dependent PLA₂ superfamily member encoded by PLA2G2D in humans.¹ It is composed of a highly-conserved calcium-binding loop, catalytic domain, sPLA₂ type II-specific disulfide that provides stability, and a C-terminal extension but lacks the N-terminal signal peptide found in sPLA₂ (Type IB) and sPLA₂ (Type X). sPLA₂ (Type IID) is expressed in the pancreas, spleen, thymus, colon, small intestine, placenta, and prostate, as well as in dendritic cells and macrophages.^2,3 It preferentially catalyzes the hydrolysis of phosphatidylethanolamine (PE) and phosphatidylglycerol (PG) over phosphatidylcholine (PC), phosphatidylserine (PS), and phosphatidic acid (PA) at the sn-2 position, liberating the free fatty acid and lysophospholipid, which serve as substrates for the synthesis of bioactive lipid metabolites.^1,2,3 sPLA₂ (Type IID) is involved in the adaptive immune response, immunosuppression, and inflammation.^3,4,5 It has bactericidal activity against M. luteus and E. coli in vitro.⁶ Knockout of Pla2g2d decreases tumor number and weight in a mouse model of skin carcinogenesis induced by 9,10-dimethylbenz(a)anthracene (9,10-DMBA) and phorbol 12-myristate 13-acetate (TPA; Item No. 10008014) and prevents resolution of ear swelling in a mouse model of contact hypersensitivity induced by the hapten antigen dinitrofluorobenzene (DNFB).^5,3 SNPs in PLA2G2D are associated with body weight loss in patients with chronic obstructive pulmonary disease (COPD).⁷ Caymans sPLA₂ (human, recombinant Type IID) protein can be used for enzyme activity assays.

WARNING This product is not for human or veterinary use.